The Webinar Training Pass
Now get all the training you need – all in one place, and all for one low price!
The FDAnews Webinar Training Pass program gives you year-round unrestricted access to any of the hundreds of webinars listed below. These training programs feature top consultants, expert speakers and FDA officials.
PLUS, subscribers get automatic access to all our new training programs for the next 12 months – that’s more than 50 new programs a year!
If you are already a Training Pass member login below and then scroll down to view the list in date order or narrow your search by keyword or category. Viewing the webinar is easy… simply identify the webinar you want to watch, click on the title and the video will begin. If you would like to view or download the presentation materials separately from the video click the "Download Presentation" link.
BUY NOW 1-Year Unlimited Access $1,297
Webinar Training Pass
FDA Adverse Event Reporting System
66 minutes
Recorded on: Dec. 18, 2019
Description: : Consultant and former FDA investigator Ricki Chase explains how to navigate the FDA’s Adverse Event Reporting System. She discusses:
- The difference between serious unexpected and serious expected events;
- Common inspection observations related to adverse events; and
- What not to report.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Ricki Chase, Executive Director, Lachman Consultant Services
Recorded on: Dec. 17, 2019
Description: A panel of quality systems experts discuss the benefits of using cloud technology solutions. They cover:
- Regulatory impact;
- Hybrid cloud approach; and
- Validating cloud solutions.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Ashley Wentworth, Director of Strategy, Vault Quality, Veeva Systems; Robert Lorence, Managing Director, PwC Consulting; Jhumki Sen, Senior Manager, PwC Consulting
Recorded on: Dec. 16, 2019
Description: Biologics development Scott Burger presents strategies for successful BLA submissions. He discusses:
- FDA requirements for cell therapy or gene therapy BLAs;
- What reviewers in the Office of Tissues and Advanced Therapies expect to see;
- How a cell or gene therapy BLA fits into the framework of the common technical document; and
- How the earlier stages in development affect the content of the BLA.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Scott Burger, Principal, Advanced Cell and Gene Therapy
Recorded on: Dec. 12, 2019
Description: Device industry veteran Jon Speer presents best practices, tips and pointers for internal company change control processes and practices. He discusses:
- The different types of change and how each should be managed;
- How to assure a risk-based approach to change management; and
- How technology solutions can help streamline change management.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Jon Speer, Co-founder and Vice President of QA/RA, Greenlight Guru
Pharmaceutical Regulation in 2020
84 minutes
Recorded on: Dec. 10, 2019
Description: A panel of experts discusses the pharmaceutical regulatory climate in the coming year. They cover:
- The impact of the new FDA commissioner;
- Drug pricing;
- Drug importation; and
- Generics competition.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Wayne Pines, President of Healthcare, APCO Worldwide; John Kamp, Washington Counsel, Coalition for Healthcare Communication; Kevin Madagan, Partner, Reed Smith; Tish Pahl, Principal, OFW Law
The Future of Generic Drug Competition
80 minutes
Recorded on: Dec. 9, 2019
Description: Intellectual property experts Chad Landmon and Neema Kumar explore FDA and congressional initiatives to promote generic drug competition. They discuss:
- Implementation of the FDA’s Drug Competition Action Plan;
- Pathways to expedited approval of generic drug applications; and
- How to obtain 180-day exclusivity.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Chad Landmon, Chair, FDA and IP practice groups, Axinn, Veltrop & Harkrider LLP; Neema Kumar, Senior IP Counsel, Hikma Pharmaceuticals USA
Recorded on: Dec. 2, 2019
Description: Regulatory specialist William Garvin provides an update on the implementation processes of the DSCSA. He discusses:
- Handling of suspect and illegitimate products;
- Confirming authorized trading partners;
- Product serialization and exchange of transaction information, transaction history and transaction statement; and
- Recent FDA enforcement actions.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: William Garvin, Attorney, Buchanan Ingersoll & Rooney PC
FDA 483s and Warning Letters: What Regulatory and Quality Professionals Absolutely Need to Know
82 minutes
Recorded on: Nov. 25, 2019
Description: Regulatory experts John Fuson and Chalana Damron share current FDA enforcement trends to prepare you for your next inspection. They discuss:
- 2019 FDA enforcement activity—483s and warning letters—versus prior years;
- The most prevalent targets of FDA inspections;
- GMP violations most often cited in 483s and in warning letters; and
- How to manage inspections to minimize the risk of escalation.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: John Fuson, Partner in the Health Care, Product Risk Management (PRM) and White Collar and Regulatory Enforcement groups; Chalana Damron, Counsel in the Mass Tort, Product and Consumer Litigation group; Crowell & Moring, LLP
Understanding UDI in EU Device Regulations
91 minutes
Recorded on: Nov. 21, 2019
Description: Device regulation expert Dan O’Leary shares the challenges of complying with unique device identification (UDI) rules and major variances from FDA regulations in preparation to meet the May 2020 deadline. He discusses:
- The EU’s UDI system;
- Requirements for devices and packages;
- The role and uses of Basic UDI-DI; and
- EU-MR Article 120 transition requirements.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Dan O’Leary, President, Ombu Enterprises, LLC
Recorded on: Nov. 19, 2019
Description: Quality expert Leslie Sam shares best practices for how to leverage ICH E8(R1) revised guidelines’ quality-by-design approaches, expanded study designs and data source considerations. She discusses:
- The scope and general principles of the ICH E8(R1) guideline;
- The impact to current research practices that may be outlined in SOPs, procedures, processes and documentation;
- The framework and approaches for identifying critical to quality factors; and
- The best way to identify clinical development areas that may be impacted by the adoption of the ICH E8(R1) guideline as well as approaches for compliance.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Leslie Sam, Principal Consultant, Wool Consulting Group
